Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 54.4% in August

Posted by Renee Jackson on Sep 15th, 2026

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 5,707 shares, a decrease of 54.4% from the August 15th total of 12,512 shares. Based on an average daily volume of 16,436 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the shares of the company are short sold.

Alaunos Therapeutics Trading Down 3.4%

NASDAQ TCRT traded down $0.05 on Tuesday, reaching $1.44. The stock had a trading volume of 9,804 shares, compared to its average volume of 16,326. Alaunos Therapeutics has a 1 year low of $1.44 and a 1 year high of $4.59. The business has a 50 day moving average price of $1.86 and a 200 day moving average price of $2.42. The company has a market capitalization of $3.66 million, a price-to-earnings ratio of -0.75 and a beta of -0.97.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Alaunos Therapeutics presently has a consensus rating of “Sell”.

Get Our Latest Report on Alaunos Therapeutics

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.